NEW YORK, September 24, 2015 /PRNewswire via COMTEX/ -- NEW YORK, September 24, 2015 /PRNewswire/ --
Q BioMed Inc QBIO, -3.64% a biotechnology acceleration and development company, President and CEO, Mr. Denis Corin was interviewed on The Wall St Analyzer.
In the interview Mr. Corin discusses Q BioMed, its vision and the recent news announcing the letter of Intent to in-license and ultimately acquire the assets of Mannin Research Inc.
The initial target of the Mannin technology platform is a therapeutic eye drop for the treatment of Glaucoma. There have been no new-class drugs developed for Glaucoma for 20 years, since Pfizer introduced Xalatan (latanaprost). The multi-billion dollar Glaucoma market is underserviced and the 60 million people suffering from the disease is expected to grow to 80 million by 2020 (W.H.O 2010). There is no cure for Glaucoma and new therapeutics are highly sought after. Current therapies and surgical procedures are not optimally effective, are painful and not well tolerated by patients. The Mannin platform is both unique and first-in-class and we are the only drug company targeting this mechanism of action.
Please listen to the interview by following this link to The Wall St. Analyzer http://wallstreetanalyzer.com/q-biomed-otcqbio-ceo-denis-corin/ or visit our website http://www.qbiomed.com
About Q BioMed Inc.
Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need?.
Help employers find you! Check out all the jobs and post your resume.
